Prevalence and prognostic implications of PD-L1 expression in soft tissue sarcomas

peer-reviewed
Erstveröffentlichung
2021-07-01Authors
Kelany, Mohamed
Barth, Thomas FE.
Salem, Dina
Shakweer, Marwa M.
Wissenschaftlicher Artikel
Published in
Pathology & Oncology Research ; 27 (2021). - Art.-Nr. 1609804. - eISSN 1532-2807
Link to original publication
https://dx.doi.org/10.3389/pore.2021.1609804Institutions
UKU. Institut für PathologieDocument version
published version (publisher's PDF)Abstract
Background: PD-L1 expression differs from 19 to 92% in various cancer subtypes. Its expression carries a worse prognostic value in various malignancies and could also be used as a predictive marker for immune checkpoint inhibitor response. This study aimed to explore the prevalence of PD-L1 expression in soft tissue sarcomas and the correlation of PD-L1 expression with clinicopathological features.
Patients and Methods: The tissue samples of 50 patients with STS were tested for PD-L1 expression using immunohistochemistry (IHC). We followed a 6-step proportional scoring system. The patients were treated at Ain Shams University Hospital from 2011 to 2017. We also explored the correlation of PD-L1 expression with different clinical features of the patients. The chi-square test was used to calculate the differences among variables.
Results: Twelve cases (24%) showed positive PD-L1 expression with the highest prevalence in rhabdomyosarcoma and desmoid tumors (2/2 and 2/3 cases, respectively), followed by GIST in 2/4 cases and liposarcoma in 3/11 cases. Patients with positive PD-L1 expression showed a trend for worse survival, with a median overall survival of 11 months vs. 19 months for patients with negative PD-L1 expression (p-value = 0.1) and a mean PFS of 6 months vs. 11 months for patients with negative PD-L1 expression (p-value = 0.1). However, these findings did not reach statistical significance.
Conclusion: Although the results did not reach statistical significance due to the small number of cases, PD-L1 expression could represent a prognostic factor for poor outcome. Larger clinical trials are recommended for the validation of PD-L1 as a poor prognostic biomarker.
Subject headings
[GND]: Sarkom | Biomarker | Prognose | Prävalenz[MeSH]: Soft tissue neoplasms | Sarcoma | Biomarkers | Prognosis | Prevalence
[Free subject headings]: PD-L1 expression | soft tissue sarcomas
[DDC subject group]: DDC 610 / Medicine & health
Metadata
Show full item recordDOI & citation
Please use this identifier to cite or link to this item: http://dx.doi.org/10.18725/OPARU-47924
Kelany, Mohamed et al. (2023): Prevalence and prognostic implications of PD-L1 expression in soft tissue sarcomas. Open Access Repositorium der Universität Ulm und Technischen Hochschule Ulm. http://dx.doi.org/10.18725/OPARU-47924
Citation formatter >